ImaCor, Inc is a biotechnology and healthcare company, founded in 2009 in the United States. The company designs, manufactures, and distributes hTEE technology, a critical care solution that provides clinicians with continuously-available, direct cardiac visualization over time. This technology, enabled through the EVO ultrasound systems and the miniaturized, disposable ClariTEE® probe, allows for episodic assessment of cardiac filling and function, remaining indwelling for up to 72 hours. Founded by dedicated cardiologists Scott Roth, M.D. and Steven Evans, M.D., along with scientist Harold Hastings, Ph.D., ImaCor's vision is to make ultrasound-guided hemodynamic management the gold standard in advanced hemodynamic management for critical care globally, significantly impacting the quality and economics of patient care.
The latest investment in ImaCor, Inc was a $5.45M Series A investment on 21 February 2009, funded by WFD Ventures and Johnson & Johnson Development Corporation. The company's innovative approach to optimizing cardiac performance and its potential to impact patient care and resource utilization make it an intriguing prospect for venture capital investment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $5.45M | 2 |
|
21 Feb 2009 |
No recent news or press coverage available for ImaCor, Inc.
We care about your data, and we'd love to use cookies make your experience better.
